We present the case of a 72-year-old woman diagnosed with multiple myeloma (MM) in 1992 and treated with lenalidomide plus dexamethasone (LD) as third-line therapy. The patient achieved a complete remission (CR) after 6 cycles of LD treatment, was treated with LD for almost 4 years, and has now been in CR for 5 years. This case illustrates the potential of lenalidomide for continuous treatment in MM, with side effects controllable through tailored patient management including step-wise dose adaptations. © 2012 Springer-Verlag.
CITATION STYLE
Müldür, E., Weißmann, A., Leitgeb, C., Zojer, N., Schreder, M., Heintel, D., & Ludwig, H. (2012). Continuous treatment with lenalidomide in multiple myeloma: A case report. Memo - Magazine of European Medical Oncology, 5(1), 23–26. https://doi.org/10.1007/s12254-012-0331-6
Mendeley helps you to discover research relevant for your work.